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Abstract
Background: Evidence has existed for decades that higher doses of rifampin may be more effective, but potentially
more toxic, than standard doses used in tuberculosis treatment. Whether increased doses of rifampin could safely
shorten treatment remains an open question.
Methods/Design: The HIRIF study is a phase II randomized trial comparing rifampin doses of 20 and 15 mg/kg/day
to the standard 10 mg/kg/day for the first 2 months of tuberculosis treatment. All participants receive standard
doses of companion drugs and a standard continuation-phase treatment (4 months, 2 drugs). They are followed for
6 months post treatment. Study participants are adults with newly diagnosed, previously untreated, smear positive (≥2
+) pulmonary tuberculosis. The primary outcome is rifampin area under the plasma concentration-time curve (AUC0–24)
after at least 14 days of study treatment/minimum inhibitory concentration. 180 randomized participants affords 90 %
statistical power to detect a difference of at least 14 mcg/mL*hr between the 20 mg/kg group and the 10 mg/kg
group, assuming a loss to follow-up of up to 17 %.
Discussion: Extant evidence suggests the potential for increased doses of rifampin to shorten tuberculosis treatment
duration. Early studies that explored this potential using intermittent, higher dosing were derailed by toxicity. Given the
continued large, global burden of tuberculosis with nearly 10 million new cases annually, shortened regimens with
existing drugs would offer an important advantage to patients and health systems.
Trial registration: This trial was registered with clinicaltrials.gov (registration number: NCT01408914) on 2 August 2011.
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Background
Nearly 10 million new cases of tuberculosis (TB) and 1.5
million deaths due to TB occur worldwide each year. Of
those who receive treatment, 86 % experience successful
outcomes [1]. Although TB treatment is currently recom-
mended for six months, it has been argued that shortening
treatment by as little as two months would accrue sub-
stantial benefits to patients and health systems [2, 3].
Consequently, studies of shortened treatment have
been implemented. These generally fall into three cat-
egories. First are studies that have assessed whether
shortened regimens would be adequate in patients with
less severe disease (represented by absence of cavitation
on radiography) [4]. The second group has investigated
regimens containing a new drug, pretomanid with or
without bedaquiline [5] (STAND:NCT02342886;NC-
005:NCT02193776). The third, and most common type
has investigated introduction or modification of doses of
existing drug classes (fluoroquinolones and rifamycins)
in treatment shortening (ReMoxTB, RIFAQUIN, OFLO-
TUB, TBTC Studies 27, 28, 29) [6–11].
Rifampin (RIF), one member of the rifamycin class, is
unique among the drugs explored for shortening potential.
It is the only drug that already has a TB indication from
multiple stringent regulatory authorities, is globally used
routinely for TB, and is cheap and produced by multiple
quality-assured generic manufacturers. Additionally, there
is an extensive body of in vitro, animal, and human
evidence suggesting that higher-than-standard daily doses
of RIF may safely and successfully shorten the 6-
month TB treatment [12–16].
For TB, RIF is dosed at 600 mg daily (10 mg/kg/day).
This dose was selected in the absence of studies optimiz-
ing daily dose and in the presence of perceived resource
constraints [17, 18]. Although in vitro and animal data
revealed concentration-dependent killing [19–25], trans-
lation of these findings to clinical studies was influenced
by the perceived high cost of rifampin at its introduc-
tion. To minimize costs, intermittent (1–3 times/week),
higher doses of rifampin for TB were explored in
humans. Increased plasma concentrations and more
rapid culture conversion were observed [26, 27]. Decroix
et al. reported that increasing the rifampin dose from
600 to 900 mg resulted in a near doubling of serum
concentrations during the two months when concentra-
tions were monitored [26]. Acocella observed tripling of
the maximum serum concentration (Cmax) with a doub-
ling of the dose of rifampin, from 10 to 20 mg/kg/day.
This is likely due to the significant saturation of rifampin
first-pass metabolism as doses were increased [28]. Thus,
significant increases in exposure are to be expected from
even modest increases in dose. The presence of toxicity
among patients receiving intermittent, higher doses of
rifampin, however, ended efforts to explore improved
activity in the 1970s [29–32]. High-dose (15–20 mg/kg)
daily rifampin has now been used for other indications
(leprosy [33], resistant Streptococcus pneumoniae [34],
staphylococcal infections of orthopedic implants [35],
Legionella jordanis [36], and cutaneous leishmaniasis
[37]) without evidence of dose-dependent toxicity. This
is consistent with the results of a recently published
maximum dose-tolerability study, which found no ser-
ious adverse events occurring at doses of up to 35 mg/
kg/day for 1- 2 weeks [38]. These observations suggest
that the serious toxicities previously associated with
high-dose RIF—particularly hepatotoxicity and flu-like
syndrome—may be idiosyncratic rather than dose re-
lated, or may be linked to intermittency [12, 14–16].
More recent work has corroborated the findings that
rifampin exposure is known to be dose-related and at
least dose-proportional [39]. One study revealed a near
quadrupling of area under the plasma concentration-
time curve (AUC)/minimum inhibitory concentration
(MIC) when rifampin dose was increased from 300 to
600 mg [40]. In an observational study of Indonesian
patients with pulmonary TB by Ruslami et al., AUC
increased by a factor of 1.65 when the rifampin dose was
increased from 450 to 600 mg [41]. The observed
increase in pharmacokinetic exposure with dose has
been linked to improved response using markers of
efficacy in humans. In studies of early bactericidal activ-
ity, a linear increase in the activity of rifampin has been
reproducibly demonstrated up to a dose of 1200 mg
[42]. This body of evidence supports the concept that
rifampin doses greater than 600 mg may increase treat-
ment response during the first two months, which could,
in turn, permit treatment shortening.
To address this question, we embarked on a Phase II
trial, entitled “Evaluation of high-dose rifampin in
patients with new, smear-positive tuberculosis” or, HIRIF.
The study is being conducted under investigational new
drug application (# 106635) with the US Food and Drug
Administration. The study protocol is presented here.
Objectives
HIRIF has three primary objectives:
1) To assess the difference in steady state pharmacokinetic
exposure of rifampin and 25-desacetyl-rifampin
across three, daily, oral doses of rifampin (10, 15 and
20 mg/kg/day). This is done through evaluation of
AUC0–24/MIC of rifampin at steady state.
2) To assess the difference in sputum culture
sterilization during the initial 8 weeks across
all three rifampin doses.
3) To compare the incidence of grade 2 or higher adverse
events related to the study drug during the 8-week
intensive phase of treatment, and up to 4 weeks later.
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Secondary objectives refine the understanding of safety
and efficacy of higher doses of rifampin and explore
potential surrogate endpoints for failure and relapse.
Methods
Design
HIRIF is a multi-site, randomized, controlled, triple-
blinded clinical trial assessing the pharmacokinetics,
efficacy, and safety of higher doses of rifampin. Two ex-
perimental arms, rifampin 15 and 20 mg/kg/day, are
compared to the control arm, rifampin 10 mg/kg/day.
The study is randomizing 180 participants to one of three
treatment arms in a 1:1:1 allocation. Randomization is
blocked, but not stratified. Unblinded pharmacy staff im-
plement treatment assignment and prepare weight-based
prescriptions providing only blinded information to
participants and other study staff.
Study participation lasts 12 months. During the first
2 months, participants receive the randomly assigned
dose of rifampin 7 days/week, in combination with
standard doses of companion anti-TB drugs: isoniazid
(H, 5 mg/kg/day), ethambutol (E, 20 mg/kg/day), and
pyrazinamide (Z, 25 mg/kg/day). All study participants
then receive a 4-month continuation phase of therapy
with standard treatment doses (H: 10 mg/kg/day; RIF:
10 mg/kg/day) 3 days/week. Throughout, 50 mg of pyri-
doxine is administered 3 times/week to prevent periph-
eral neuropathy, a common side effect of isoniazid.
Study participants are followed for 6 months after treat-
ment completion (see Fig. 1).
Setting
HIRIF is being implemented in two districts in Lima,
Peru (Lima Este and Lima Ciudad) where the local
implementing partner, Socios En Salud (SES), operates.
The year prior to study initiation, approximately 2500
cases of smear-positive TB were reported in the catch-
ment area. Less than 4 % of TB cases were co-infected
with human immunodeficiency virus (HIV) and roughly
10 % had diabetes mellitus. Potential participants are
identified in 43 peripheral health centers and then referred
to either Hospital Nacional Hipólito Unanue (HNHU) or
Hospital Nacional Sergio E. Bernales (HNSEB), according
to jurisdiction. Both hospitals are research centers certi-
fied by the Peruvian National Institute of Health (INS).
The National TB Program of Peru endorsed the study
and provides oversight and supervision to the recruit-
ing health centers and research centers. Pre-screening
sputum microscopy is performed by health center la-
boratories. Study microbiology is performed by the
SES research microbiology laboratory, which is quality
assured by the Peruvian INS and the College of
American Pathologists. A research pharmacy approved
by the Peruvian national regulatory authority and a
private clinical lab completed the site resources.
Study population and eligibility
The study population comprises adults with newly diag-
nosed, previously untreated, smear positive (≥2+) pul-
monary tuberculosis. Patients who meet these criteria on
presentation to ambulatory care facilities in the two
Fig. 1 Flow of 12-month study participation
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districts are invited to participate. They are then referred
to study staff at the research centers for informed con-
sent and eligibility screening.
Main inclusion criteria for participation in HIRIF
are newly diagnosed, pulmonary TB with acid-fast ba-
cilli (≥2+) in a stained sputum smear, and susceptibil-
ity to isoniazid and rifampin detected by HAIN
MTBDR+ test. Eligible participants are adults (18–60
years old), ≥30 kg, who have never been treated with
multidrug anti-TB therapy for more than one month
and who have no known intolerance or contraindica-
tions to the study drug or companion drugs, and who
are not taking any additional drugs for which there
may be potential negative drug interactions, synergistic
toxicities, or contraindications. Other criteria include a
Karnofsky score of ≥50. The following exclusions apply:
central nervous system or miliary TB; pericardial or
pleural involvement; significant hemoptysis; any un-
controlled condition that may interfere with drug absorp-
tion, distribution, metabolism or excretion; uncontrolled
diabetes mellitus (glycocylated hemoglobin >7.5 %); ser-
ology positive for hepatitis B virus surface antigen or hepa-
titis C virus antibody; pulmonary silicosis; history of liver
disease or current amino alanine transferase greater than 2
times the upper limit of normal (ULN); total bilirubin
concentration greater than 2.5 times the ULN, creatinine
concentration greater than two times the ULN (or creatin-
ine clearance <60 mL/min), hemoglobin concentration
<7.0 g/dL, platelet count <150,000/mm3, or white blood cell
count <4500 cells/μL. Women of child-bearing potential
must not currently be pregnant or breastfeeding and must
agree to practice an effective double-barrier method of
birth control during treatment. All participants must be
willing to undergo HIV testing according to the National
Health Guidelines for TB control in Peru; however, patients
can be included in the trial regardless of HIV status. Finally,
all participants must willingly sign the informed consent
form, intend to remain within the jurisdiction of the health
center throughout the study to facilitate monitoring and
completion of follow-up, and be assessed to be capable of
adhering to the study protocol.
Treatment delivery and retention
All study treatment doses are directly observed. Reten-
tion is assured through a system of treatment support
and enablers. All treatment is ambulatory and delivered
by dedicated directly observed therapy (DOT) supporters.
Treatment adherence is assessed through reviews of
treatment logs throughout the intensive and continu-
ation phases. Transport costs for study visits are cov-
ered by the study. Participants receive regular food
vouchers for their participation and meals during pro-
longed study visits.
Assessment of study endpoints
The primary pharmacokinetic (PK) endpoint, area under
the concentration curve (AUC0–24), is assessed through
blood sampling on a single day after steady state rifam-
pin exposure is achieved [43] and before the interven-
tion dose is discontinued, between 15 and 56 days post
randomization. Participants are randomly assigned to ei-
ther a sparse (samples are collected pre-dose and at two
timepoints after dosing) or intensive (samples are col-
lected pre-dose and at six timepoints after dosing) PK
sampling group in a 2:1 allocation. Because AUC0–24/MIC
is thought to be the pharmacokinetic-pharmacodynamic
(PK-PD) parameter best correlated with anti-TB activity
[21], the MIC of each participant’s pre-treatment infecting
isolate is also estimated from early morning and overnight
sputum samples collected at the pre-treatment visit.
The primary efficacy endpoint, change in M. tubercu-
losis log10 colony forming units (CFU) in sputum, is
assessed by counting log10 CFUs in sputum cultures,
grown in 7H11 Middlebrook medium. Samples from the
same timepoints are also cultured in the BACTEC 960
system (MGIT). These are used to estimate time to cul-
ture conversion and change in time to positivity
in MGIT. All participants are sampled at baseline, then
at 5 time points during intensive phase. Information
from sequential pooled sputum samples is used to calcu-
late decline in log10 CFUs. Additional early-morning
sputum samples are collected for smear microscopy and
culture in Löwenstein Jensen medium.
The occurrence of adverse events, use of concomitant
medications, and risk of pregnancy and/or breastfeeding
are assessed at each study visit. Laboratory screenings are
performed to identify hematologic and biochemical abnor-
malities throughout the study period. Clinical and labora-
tory findings are graded by clinical investigators according
to the modified Adult Toxicity Table [Draft Nov. 2007] for
the Division of Microbiology and Infectious Diseases
(DMID), National Institute of Allergy and Infectious
Diseases (NIAID), National Institutes of Health (NIH).
Analysis (including power calculation)
The study population of 180 patients (60 per treatment
arm) is based on the following assumptions for PK, effi-
cacy, and safety. Existing unpublished data suggest a
minimum increase in AUC0–24 of 12 mcg/mL*hr across
dose groups. Assuming a standard deviation of AUC0–24
of 24 mcg/mL*hr and α = 0.05, a linear contrast test
across the three treatment groups, the study affords
90 % power to detect a total effect size of 14 mcg/mL*hr
between the top and bottom dose levels at a sample size
of 50 evaluable subjects per arm, permitting a 17 % loss
to follow up.
The estimation of the sample size for the efficacy end-
point is based on computation of the population Fisher’s
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Information matrix derived from linearization of a non-
linear mixed effects model for the data. The parameter,
θ4, in this model represents the late phase decay in col-
ony counts, a surrogate measure of sterilizing activity.
Under conventional assumptions of α = 0.05 and ß = 0.20
with a coefficient of variation on θ4 of 20 %, a sample
size of 48 per arm is sufficient to detect a difference
between the highest and lowest dose arms of 0.025
log10 CFU/ml. This is comparable in magnitude to
differences observed in previous colony counting studies.
A sample size of 60 per arm allows up to 25 % patient
withdrawals.
Among adverse events thought to be associated with
rifampin dose, hepatotoxicity is one of the most worry-
ing. Hepatotoxicity has been observed to occur in up to
27 % of patients receiving RIF-containing regimens for
TB, with the summary frequency from one meta-analysis
estimated at 2.7 % [44]. Other serious toxicities, such as
hematologic disorders and flu-like syndrome are esti-
mated to occur in between 1 and 5 % of patients on
standard doses of RIF [45]. In a pivotal trial of rifapen-
tine (compared to standard doses of RIF) 5 % of subjects
receiving rifampin permanently discontinued treatment
[45]. We expect at least 10 % of patients in the control
arm to experience a grade 2 or higher event related to
RIF. We have 62 % power (1-sided α = 0.1) to detect
adverse events occurring twice as frequently in the inter-
vention arms combined, and greater than 95 % power to
detect a relative risk of ≥3. Since we are comparing
incidence of adverse events, a continuous variable, the
statistical power afforded by the study sample size is
actually slightly higher.
Analysis of primary endpoints
The primary PK analysis will be a two-sided linear con-
trast test of dose-response of AUC0–24/MIC across the
three dose groups with a significance level of 5 %. Second-
ary analyses of the summary parameters will include simi-
lar tests of dose-response for AUCo-∞ and Cmax.
Exploratory analyses of additional determinants of the ex-
posure parameters (AUC0–24, AUCo-∞ and Cmax) and
clearance will include as covariates study site, body mass
index, sex, and plasma concentration of companion drugs.
Population PK modeling of the parent compound and
its major metabolite, 25-desacetylrifampicin, using the
rich and complete datasets will be carried out.
The primary efficacy analyses will be two-sided linear
contrast tests of the three dose levels on: 1) the param-
eter θ4 (late-phase sterilizing slope) derived from non-
linear mixed effects modeling and 2) the hazard ratio of
culture conversion in MGIT derived from the Cox pro-
portional hazards model at a significance level of 5 %.
These two endpoints, and their performance characteris-
tics for predicting failure/relapse, will be compared with
each other, and with the binary 2-month LJ culture con-
version endpoint.
To evaluate the effect of dose size on adverse events
(AEs) grade 2 or higher, the primary analysis will be a
comparison, between the intervention groups and the
control group, of time to adverse events occurring in the
first 12 weeks after randomization and determined to be
related to rifampin. In secondary analyses, the rate of
discontinuation due to hepatotoxicity will be compared
between the intervention groups and the control group.
If a significant difference is detected, comparison will be
made between the 15 mg/kg intervention group and the
control as well as between the 20 mg/kg intervention
group and the control.
Dissemination of trial findings
The study principal investigators hold primary re-
sponsibility for the preparation of publications. Once
the trial is complete, the investigators anticipate
publishing results of this study in several manuscripts
in peer-reviewed scientific journals. In compliance
with the policy of International Committee of Medical
Journal Editors, this trial is registered in ClinicalTrials.gov:
NCT01408914.
Discussion
The HIRIF trial is a Phase IIB design that incorporates
several approaches that are novel in the tuberculosis
field. Most importantly, the study is designed to fully
support a rigorous pharmacokinetic-pharmacodynamic
analysis, which is appropriate to the goals of an early-
phase dose-ranging trial. The pharmacokinetic aspect of
the study is based on a population approach which is
facilitated by the intensive-sparse sampling design and
enables pharmacokinetic exposure (AUC0–24) to be esti-
mated for all participants in the study. In addition, RIF
MIC will be obtained for each participant enabling more
direct comparisons with existing preclinical data for the
first time in a human clinical trial and accounting for
this important source of variability in treatment re-
sponse [46]. Finally, for increased statistical power [21],
the pharmacodynamic outcomes are powered on the basis
of quantitative bacteriology, specifically serial sputum col-
ony counting, rather than on the more traditional two-
month culture conversion endpoint. A balanced-blocks
design of staggered sputum sampling times based on prior
studies was adopted to make this approach convenient
for patients and logistically feasible for the laboratory
[47]. Several alternative biomarkers of treatment re-
sponse are also being evaluated using these samples.
HIRIF addresses an important evidence gap in the
treatment of TB. Although the work that led to the im-
plementation of the 6-month, 4-drug regimen containing
daily, 600 mg doses of rifampin was highlighted as a
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model for medical interventions [48], the optimal dosing
for rifampin was overlooked in the series of trials that
led to these laudatory remarks. Cost trumped efficacy in
the selection of regimens tested in the Medical Research
Council trials that led to the development of the current
standard of care. That tens of millions of patients may
have been subjected to suboptimal doses is an inexcus-
able tragedy, which must not be repeated in future drug-
development efforts. In the case of rifampin, cost is no
longer an issue as it is currently produced by several
quality-assured manufacturers and sold for pennies
per dose: 3.7–4.7 cents per 150-mg rifampicin tablet/
capsule, or 7.3–8.5 cents per 300-mg rifampicin tablet/
capsule [49].
Results from HIRIF will complement those from other
recently conducted studies. These include another Phase
II study conducted by the PANACEA Consortium in
Tanzania, known as HIGHRIF2 (NCT00760149). This
study examined the same doses of rifampin in 180
participants with similar endpoints. Both studies were
powered for the PK endpoints, which required smaller
sample sizes than efficacy and safety endpoints. Data
from the two studies will be pooled to provide greater
power to assess dose-related efficacy and toxicity end-
points. PANACEA also has conducted a maximum-dose
tolerability study, HIGHRIF1 [38]. Among participants
who received up to 35 mg/kg of RIF, both monotherapy
and multidrug therapy, there were no serious adverse
events. In light of this information, the consortium
embarked on a Phase II/III adaptive study, MAMS-TB-
01 trial (NCT01785186), that examined rifampin doses
of 35 mg/kg in combination therapy. Lastly, RIFATOX
(ISRCTN55670677), a toxicity study of higher doses
(600 mg vs. 900 and 1200 mg) of rifampin found no
association between rifampin dose and toxicity. When
HIRIF results are available, we will examine the whole
body of recently generated evidence to determine if and
what further investigation is necessary. Options include
additional Phase II work with higher doses for longer
duration than in HIGHRIF1. Also possible is moving
forward with Phase III studies of either the 15 or 20 mg/
kg dose, depending on results from HIRIF and results
pooled with HIGHRIF2. Any proposed study would
complement those already conducted or underway (i.e.,
PANACEA, the proposed RIFASHORT [NCT02581527]).
And, it is possible that based on combined efficacy and
safety data, there will be no justification for further investi-
gation of higher doses of rifampin for new, smear-positive
pulmonary TB. Irrespective of the final outcome, however,
we can be confident that an historical wrong has been
righted: the dose of rifampin used for TB in the future
will reflect the complete evidence on PK, efficacy, and
safety assessed using modern methods, available in
the 21st century.
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